2023
10-year Anniversary
At 2 Bridge, we firmly believe that the strength of a strong, trusted, cross-functional team that works in a synergistic ‘Tiger Team’ manner, is of great value for those venturing into life sciences, including investors, startups, biotechs, and pharma.
We offer end-to-end solutions across all drug development areas, including strategy and implementation; preclinical, translational science, clinical, CMC, quality; healthcare product development, and company building.
Our Way of Working
You are the owner of the building, and we act as your architects.
We do not only DESIGN innovative and ambitious plans to drive science forward or establish a fit-for-purpose organization. We also EXECUTE the plans and ensure the outcomes deliver the envisaged value, to you as a client and ultimately to the patients in need.
We Master TEAMING.
Our deep experience in seamlessly integrating within the client organization and adapting to the organization’s dynamics is what our TEAMING is all about. Our TEAMING enables us to kick-start an effective and TRUSTWORTHY collaborative spirit. A collaborative spirit forms the basis of a culture where people NURTURE each other through constructive feedback and grow together while delivering.
Show GRIT in everything we do.
GRIT reflects our passion and perseverance. Our PASSION for bringing Science to Life, establishing fit-for-purpose organizations, and for highly effective and efficient collaborations is noticeable from our ever ‘sparkling eyes’. Our PERSEVERANCE gets reflected in our agility to adapt to circumstances and focus on finding a way to deliver on challenging goals in complex circumstances.
How we collaborate with clients...
Values that drives us forwards...
Management
Team
Ann holds a Ph.D. in Science from the University of Antwerp (Biology/Pharmacology) and a Master in Management from UA and Middle Management MBA from Vlerick Business School. Currently, she is the CEO, one of the managing partners, and co-founders of 2 Bridge.
Ann has extensive experience (30+ years) in drug development. In her previous role as a compound development team leader in a big pharma company, she brought several products from discovery to the early clinical proof of concept phase and subsequently led and managed the early development portfolio of a spinout company. Amongst others, Ann has guided a clinical-stage biotech as Chief Development Officer, while supporting several companies in evaluating, selecting, and developing products, often in interim management roles (CSO/CEO).
Tomas has more than 30 years of experience in financial management in both big multinationals and small, local companies covering a broad range of industries. After starting his career at Procter & Gamble, he turned to the pharma industry by joining Johnson & Johnson, where he held various financial roles in production and commercial organizations. Banking on that experience he became Finance Director at Movetis, a spin-off from Janssen Pharmaceutica. After that, Tomas held Finance Director and CFO roles in various Belgian companies with a focus on business partnership, process excellence, and strategic finance.
Currently, Tomas is CFO at 2 Bridge, AbolerIS Pharma, and DeuterOncology.
Birgen gained progressively experience (15 years) in Clinical Development, developing his career in both a CRO environment as well as in small biotech and large pharmaceutical companies. With his refined project and vendor management skills, Birgen successfully led global pivotal trials towards drug registration. He strives for efficiency by optimizing operating processes and by maximizing collaborators’ engagement while safeguarding quality and budget.
To date, he is mainly involved in overseeing the clinical operational management of the various trials within a drug development program.
Leen has over twenty years of experience in Research and Development, from drug discovery to early clinical development. She previously worked at Johnson & Johnson, 4AZA-Elbion, Movetis, and Shire where she worked on a variety of projects in bringing compounds from target identification to clinical proof-of-concept, with a track record in translational strategy and personalized medicine, including biomarkers and patient-related outcomes.
Leen also acted as Chief Development Officer at Dynacure, where she established the basis of the overall development strategy for its lead program in CNM.
Milestones
Milestones
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013